🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "huge turning point" in the fight against superbug strains of the infection, according to health experts.

An International Challenge

Cases of gonorrhoea are escalating around the world, with data suggesting in excess of 82 million instances per year. Particularly high rates are observed in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Medical experts are increasingly worried about the rise in drug-resistant strains. The World Health Organization has listed it as a "high-priority threat". Ongoing monitoring showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Receive Approval

One new antibiotic, also known as Nuzolvence, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GSK, gained clearance in close succession. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This milestone signifies a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Clinical Trial Results and Worldwide Availability

Based on data released by a major medical journal, zoliflodacin cured over nine in ten of uncomplicated infections. This establishes an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The trial involved nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the authority to make available and distribute the drug in numerous regions with limited resources.

Clinicians on the front lines have shared hope. Having a easy-to-administer therapy of this kind is seen as a "critical tool" for managing the epidemic. This is deemed vital to lessen the impact of the illness for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.